{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-002652","form_type":"8-K","ticker":"REVB","cik":"0001810560","company_name":"REVELATION BIOSCIENCES, INC.","filed_at":"2023-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.688021+00:00","generated_at":"2026-06-19T16:27:16.514643+00:00","sec_items":["1.01","3.03","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Revelation Biosciences raises $15.6M in public offering; believes it regains Nasdaq compliance","bullets":["Gross proceeds of ~$15.6M from sale of 2.89M shares and pre-funded warrants, plus 6.45M warrants at $5.36 exercise price.","Net proceeds of ~$14.1M to fund REVTx-100 and REVTx-300 development, including Phase 1a/1b studies and manufacturing.","Company believes it now meets Nasdaq's $2.5M stockholders' equity requirement; bid price compliance at 9 of 10 consecutive days.","Officers and directors subject to 90-day lock-up; institutional investors have leak-out limiting sales to 25% of trading volume until April 10."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-002652","json":"https://secwatch.observer/filing/0000950170-23-002652.json","markdown":"https://secwatch.observer/filing/0000950170-23-002652.md","text":"https://secwatch.observer/filing/0000950170-23-002652.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810560/000095017023002652/0000950170-23-002652-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810560/000095017023002652/revb-20230209.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T16:27:16.514643+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"087f083696e08aa434a632d33bca04bf247f44c5","claim":"REVELATION BIOSCIENCES, INC. entered into Placement Agency Agreement with Roth Capital Partners, LLC valued at gross proceeds of approximately $15.6 million (effective 2023-02-09).","evidence_excerpt":"On February 9, 2023, Revelation Biosciences, Inc., (the “Company”), entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810560/000095017023002652/0000950170-23-002652-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Roth Capital Partners, LLC"},{"label":"Value","value":"gross proceeds of approximately $15.6 million"},{"label":"Effective","value":"2023-02-09"}],"fact_type":"material_agreement"},{"claim_id":"505a3d6c112a1d6e2c4c27139b7c1033ee4e78f0","claim":"REVELATION BIOSCIENCES, INC. entered into Purchase Agreement with certain purchasers valued at gross proceeds of approximately $15.6 million (effective 2023-02-09).","evidence_excerpt":"a securities purchase agreement (the “Purchase Agreement”) with certain purchasers for the purchase and sale, in a registered public offering by the Company (the “Public Offering”), of (i) an aggregate of 2,888,600 shares of its common stock","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810560/000095017023002652/0000950170-23-002652-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain purchasers"},{"label":"Value","value":"gross proceeds of approximately $15.6 million"},{"label":"Effective","value":"2023-02-09"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}